GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: STI-1558 | STI1558
Compound class:
Synthetic organic
Comment: Olgotrelvir (STI-1558) is a novel antiviral prodrug compound that is active as a dual inhibitor of viral and host proteases [2]. The active form is called AC1115. Mechanistically olgotrelvir inhibits SARS-CoV-2 3CL protease (Mpro) and human cathepsin L. It disrupts both viral entry (host protease dependent) and replication (Mpro dependent) and was developed as a potential treatment for COVID-19.
|
|
No information available. |
Summary of Clinical Use ![]() |
Olgotrelvir (STI-1558) is a clinical candidate for the treatment of COVID-19. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05716425 | Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19) | Phase 3 Interventional | Zhejiang ACEA Pharmaceutical Co. Ltd. | 1 |